Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Moss

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2015
The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosisBojana Mirković, Gillian M Lavelle, Ahmed Abdul Azim, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Pediatric Pulmonology|January 22, 2020
Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung diseaseTerry E Robinson, Michael L Goris, Richard B Moss, et al.
Human Gene Therapy|August 10, 2007
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trialRichard B Moss, Carlos Milla, John Colombo, et al.
The Journal of Allergy and Clinical Immunology|January 31, 2012
Fungi and allergic lower respiratory tract diseasesAlan P Knutsen, Robert K Bush, Jeffrey G Demain, et al.
Human Gene Therapy|August 7, 2002
A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomiesJohn A Wagner, Ilynn B Nepomuceno, Anna H Messner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2023
Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialJoseph E Levitt, Haley Hedlin, Sophie Duong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2023
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug DevelopmentCaroline J Jjingo, Shukal Bala, Ursula Waack, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2015
The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosisBojana Mirković, Gillian M Lavelle, Ahmed Abdul Azim, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Pediatric Pulmonology|January 22, 2020
Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung diseaseTerry E Robinson, Michael L Goris, Richard B Moss, et al.
Human Gene Therapy|August 10, 2007
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trialRichard B Moss, Carlos Milla, John Colombo, et al.
The Journal of Allergy and Clinical Immunology|January 31, 2012
Fungi and allergic lower respiratory tract diseasesAlan P Knutsen, Robert K Bush, Jeffrey G Demain, et al.
Human Gene Therapy|August 7, 2002
A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomiesJohn A Wagner, Ilynn B Nepomuceno, Anna H Messner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2023
Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialJoseph E Levitt, Haley Hedlin, Sophie Duong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2023
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug DevelopmentCaroline J Jjingo, Shukal Bala, Ursula Waack, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 7